Biotechnology companies operating in the fields of medicine and pharmaceuticals face extraordinary ethical challenges. The uniqueness of their biotechnological products, which cannot be equated with ordinary consumer goods, necessitates the assumption of both bioethical and corporate ethical responsibilities. The ethical management measures employed by the three leading American companies in the red biotechnology sector—Genentech Inc., Amgen Inc., and Genzyme Corp.—to meet this demand are explained through case studies. The corporate ethical question regarding the extent of each company's moral conduct under competitive conditions is the focus of the analysis. The mentioned companies primarily utilize institutionalized rather than informal ethical management measures.